Abha Kundi

NDSee You In 2033: FDA's 12‑Digit NDC Is Coming

CMS ACCESS Model Update: Payment Rates And Performance Targets Released For 2026–2027

The Regulatory Roadmap: Five Critical Questions For Evaluating Regulatory Risk For Longevity Companies

The Eyes Have It: FDA Approves Phase 1 Clinical Trial Of Life Biosciences' Reprogramming Therapy For Vision Loss